Mar 2, 2023 TWi Pharmaceuticals, Inc. (“TWi”) today announced the official launch of Testosterone Topical Solution CIII (Equivalent to Axiron®) via its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc. Product is available for immediate shipment.
 
Testosterone Topical Solution is indicated for hormone replacement in men who are not able to produce enough testosterone (hypogonadism).  According to IQVIA data, the total sales of Testosterone Topical Solution in the US were approximately US $9.8 million for the 12 months ended January 2023
 
About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier to entry generic prescription products ranging from oral controlled release dosage forms to novel drug delivery systems including the utilization of nanoparticles and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit www.twipharma.com